Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Cost-Effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Supportive care				Active				18 and over				Pharmaceutical / Industry				CR002455 NCT00264108


2.		Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Supportive care				Active				18 and over				Pharmaceutical / Industry				CR005596 NCT00398749


3.		A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Subjects With Metastatic Breast Cancer Receiving Standard Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 and over				Pharmaceutical / Industry				CR005143 NCT00338286

Last Modified: 7/11/2007 First Published: 5/23/2007


4.		Phase III Randomized Study of Recombinant Epoetin Alfa or Epoetin Beta With Versus Without Parenteral Iron in Anemic, Iron-Replete Patients With Nonmyeloid Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				Over 16				Other				BARTS-06/Q0605/93 ISRCTN11830961, EU-20731, 06/Q0605/93, NCT00482716


5.		A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				Not specified				Other				2005-0890 NCT00656448


6.		A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CR013651 EPOANE3018, NCT00695396


7.		Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-Cis-Retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				EPO2006-AISSM04 2006-006482-16, NCT00804050


8.		Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				HOG MDS04-85 NCT00379912


9.		Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				Over 18				Other				ETAMINE NCT00517621


10.		Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				Other				2004-0253 NCT00520468

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute